Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EPIDEMIOLOGY
5 REGULATORY FRAMEWORK
6 PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA
7.1.2 INCREASING WOMEN POPULATION
7.1.3 RISE IN GERIATRIC POPULATION
7.1.4 ADVANCEMENTS IN SURGICAL TREATMENT OF THE DISEASE
7.1.5 INCREASED ECONOMIC BURDEN
7.2 RESTRAINTS
7.2.1 HIGH SURGICAL COSTS OF PACG
7.2.2 INADEQUATE REIMBURSEMENT SCENARIO
7.2.3 DELAYED AND MISDIAGNOSIS OF PACG
7.3 OPPORTUNITIES
7.3.1 INCREASING GOVERNMENT INITIATIVES TOWARDS GLAUCOMA
7.3.2 RECENT APPROVAL BY GOVERNING BODIES
7.3.3 INCREASING INCIDENCES IN EMERGING MARKET
7.3.4 RAPID TRANSITION FROM PACG MEDICATION TO SURGERIES
7.4 CHALLENGES
7.4.1 RISKS ASSOCIATED WITH SURGICAL PROCEDURES
7.4.2 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE
7.4.3 LIMITED ACCESS TO TREATMENT
8 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION BY MANUFACTURERS
8.5 CONCLUSION
9 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 ACUTE ANGLE-CLOSURE GLAUCOMA MARKET
9.3 CHRONIC ANGLE-CLOSURE GLAUCOMA MARKET
10 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE
10.1 OVERVIEW
10.2 DIAGNOSIS
10.2.1 PRIMARY TEST
10.2.1.1 GONIOSCOPY EXAMINATION
10.2.1.2 SLIT-LAMP EXAMINATION
10.2.1.3 AUTOMATIC STATIC PERIMETRY
10.2.2 SECONDARY TEST
10.2.2.1 ULTRASOUND BIOMICROSCOPY
10.2.2.2 ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY (OCT)
10.2.2.3 RETINAL OCT
10.2.2.4 FUNDOSCOPY
10.2.2.5 OTHERS
10.3 TREATMENT
10.3.1 SURGICAL IRIDECTOMY
10.3.2 TRABECULECTOMY
10.3.3 MICRO INVASIVE GLAUCOMA TECHNIQUE (MIGS)
10.3.4 GONIOTOMY
10.3.5 OTHERS
11 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 AMBULATORY SURGICAL CENTERS
11.4 SPECIALTY CLINICS
11.5 OTHERS
12 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY GEOGRAPHY
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 EGYPT
13.1.3 SAUDI ARABIA
13.1.4 ISRAEL
13.1.5 UAE
13.1.6 KUWAIT
13.1.7 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT
16 COMPANY PROFILES
16.1 JOHNSON & JOHNSON VISION CARE, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 BAUSCH & LOMB INCORPORATED (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 ALCON INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 ZEISS INTERNATIONAL
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 NOVA EYE MEDICAL LIMITED
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 NIDEK CO., LTD
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 APPASAMY ASSOCIATES
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 AUROLAB
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 BVI
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 LIGHTMED
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 LUNEAU TECHNOLOGY USA
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 MEDISONIC EQUIPMENTS PVT. LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 MICROSURGICAL TECHNOLOGY
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 NEW VISION
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 NEW WORLD MEDICAL, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 OERTLI INSTRUMENTE AG
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 OMNI LENS
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 REICHERT, INC. (A BUSINESS UNIT OF AMETEK.INC.)
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENTS
16.2 SIGHT SCIENCES, INC.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, PIPELINE ANALYSIS
TABLE 2 NUMBER OF OPHTHALMOLOGISTS/MILLION POPULATIONS
TABLE 3 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA ACUTE-ANGLE CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA CHRONIC ANGLE-CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET,BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA HOSPITALS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA DIRECT TENDER IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA RETAIL SALES IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 31 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 32 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 33 SOUTH AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 34 SOUTH AFRICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 35 SOUTH AFRICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 36 SOUTH AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 37 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 40 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 41 EGYPT DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 42 EGYPT PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 43 EGYPT SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 44 EGYPT TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 45 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 47 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 48 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 49 SAUDI ARABIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 50 SAUDI ARABIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 51 SAUDI ARABIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 52 SAUDI ARABIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 53 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 56 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 57 ISRAEL DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 58 ISRAEL PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 59 ISRAEL SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 60 ISRAEL TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 61 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 64 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 65 UAE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 66 UAE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 67 UAE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 68 UAE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 69 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 72 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 73 KUWAIT DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 74 KUWAIT PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 75 KUWAIT SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 76 KUWAIT TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 77 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 79 REST OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION
FIGURE 12 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA AND ADVANCEMENT IN SURGICAL TREATMENT OF THE DISEASE ARE DRIVING THE MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 ACUTE ANGLE-CLOSURE GLAUCOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET
FIGURE 15 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020
FIGURE 16 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, CAGR (2020-2028)
FIGURE 18 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020
FIGURE 20 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE 2020-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020
FIGURE 24 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 28 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SNAPSHOT (2020)
FIGURE 32 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020)
FIGURE 33 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2021 & 2028)
FIGURE 34 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020 & 2028)
FIGURE 35 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY TYPE (2021-2028)
FIGURE 36 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY SHARE 2020 (%)
